KALETRA ORAL SOLUTION Rx

Select the drug indication to add to your list

KALETRA ORAL SOLUTION

Viral infections
Only 4 drugs may be compared at once

Generic Name and Formulations:

Lopinavir 80mg, ritonavir 20mg; per mL; cotton candy flavor; alcohol 42.4%.

Company:

AbbVie

Select therapeutic use:

Indications for KALETRA ORAL SOLUTION:

HIV-1 infection, in combination with other antiretroviral agents.

Adult:

Swallow tabs whole; take oral soln with food. ≥18yrs: lopinavir/ritonavir 400/100mg (two 200/50mg tabs or 5mL) twice daily or 800/200mg (four 200/50mg tabs or 10mL) once daily (in patients with <3 lopinavir resistance-associated substitutions). Once-daily administration not recommended if ≥3 lopinavir resistance-associated substitutions or if given in combination with carbamazepine, phenobarbital, phenytoin, efavirenz, nevirapine, nelfinavir, or if pregnant (avoid oral soln). Concomitant efavirenz, nevirapine, or nelfinavir: 500/125mg (two 200/50mg tabs + one 100/25mg tab) or 520/130mg (6.5mL) twice daily.

Children:

May use tabs if able to swallow whole and ≥15kg. Take oral soln with food. Postnatal age <14days or postmenstrual age of <42weeks: not recommended. 14days–6months: lopinavir/ritonavir 16/4mg/kg or 300/75mg/m2 twice daily. Do not administer with efavirenz, nevirapine, or nelfinavir. >6months–<18yrs: lopinavir/ritonavir 230/57.5mg/m2 twice daily, or if <15kg: 12/3mg/kg twice daily; ≥15–40kg: 10/2.5mg/kg twice daily; >40kg: max 400/100mg twice daily. Concomitant efavirenz, nevirapine, or nelfinavir: >6months–<18yrs: 300/75mg/m2 twice daily, or if <15kg: 13/3.25mg/kg twice daily; ≥15–45kg: 11/2.75mg/kg twice daily; >45kg: max oral soln: 533/133mg (6.5mL) twice daily; or max tabs: 500/125mg twice daily. See full labeling.

Contraindications:

Drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions. Potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance (eg, alfuzosin, dronedarone, colchicine (in renal and/or hepatic impairment), rifampin, sildenafil [Revatio], cisapride, ergots, elbasvir/grazoprevir, lurasidone, pimozide, St. John's wort, lovastatin, simvastatin, oral midazolam, triazolam).

Warnings/Precautions:

Suspend if pancreatitis occurs. History of, or risk factors for, pancreatitis (eg, elevated triglycerides). Hepatic impairment. Hepatitis or cirrhosis. Monitor: lipids at baseline then periodically, ALT/AST in liver disease, for hyperglycemia, or new onset/exacerbation of diabetes. Hemophilia (monitor for spontaneous bleeding). Avoid in congenital long QT syndrome or hypokalemia. Underlying structural heart disease. Pre-existing conduction system abnormalities. Ischemic heart disease. Cardiomyopathies. Toxicity in preterm neonates (see full labeling). Elderly. Pregnancy. Nursing mothers: not recommended.

Interactions:

See Contraindications. Salmeterol, boceprevir, simeprevir, ombitasvir/parataprevir/ritonavir and dasabuvir: not recommended. Avoid oral soln with metronidazole, disulfiram. Potentiates statins metabolized by CYP3A; use atorvastatin with caution and at the lowest necessary doses; do not exceed rosuvastatin 10mg daily. Potentiates sildenafil, vardenafil, tadalafil (reduce dose of these); avanafil, fluticasone (avoid). Potentiates fentanyl, parenteral midazolam; monitor. Potentiates anticancer agents (eg, vincristine, vinblastine, dasatinib, nilotinib); may need dose adjustment (see full labeling). Concomitant colchicine (see full labeling). Potentiates bosentan (see full labeling). Increases levels of antiarrhythmics (eg, amiodarone, bepridil, systemic lidocaine, quinidine), dihydropyridine CCBs, immunosuppressants (monitor); ketoconazole, itraconazole (avoid high doses), isavuconazonium sulfate (caution); bedaquiline (use only if benefit outweighs the risk); rifabutin (reduce rifabutin dose and monitor); clarithromycin (reduce clarithromycin dose in renal dysfunction), trazodone (reduce trazodone dose), maraviroc (give max maraviroc 150mg twice daily), quetiapine (reduce dose). Monitor other antiretrovirals, warfarin. Avoid concomitant rivaroxaban; increased bleeding risk. Decrease levels of atovaquone, methadone, bupropion, estrogen-containing oral contraceptives (use other or back-up contraception), voriconazole (avoid and use alternatives). Lopinavir levels decreased by anticonvulsants (eg, carbamazepine, phenobarbital, phenytoin), budesonide, dexamethasone, prednisone, efavirenz, nevirapine. Lopinavir levels may be increased by delavirdine, CYP3A inhibitors. May decrease lamotrigine, valproate, zidovudine or abacavir levels. Give didanosine 1 hour before or 2 hours after. Avoid concomitant with other drugs that prolong the QT interval. See full labeling.

See Also:

KALETRA

Pharmacological Class:

Protease inhibitor.

Adverse Reactions:

Diarrhea, nausea, vomiting, hypertriglyceridemia, hypercholesterolemia, asthenia, headache, abdominal pain, rash, insomnia, pancreatitis, fat redistribution, immune reconstitution syndrome, PR & QT prolongation.

How Supplied:

100mg/25mg—60; 200mg/50mg—120; Soln—160mL (w. dose cup)